@article{JTD24487,
author = {Yong Zhang and Ling Ye and Huijun Zhang and Xuehua Chen and Haiying Ji and Gang Chen and Lu Zhang and Tengfei Zhang and Meiling Jin},
title = {A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {10},
year = {2018},
keywords = {},
abstract = {Lung cancer is the leading cause of cancer death worldwide (1). Non-small cell lung cancer (NSCLC) causes 85% of the cases, and small cell lung cancer (SCLC) accounts for the other 15% (2). Activating alterations of epidermal growth factor receptor (EGFR) lead to 10–15% and 30–40% of NSCLC, especially adenocarcinoma, in Caucasus and Asian patients (3). In contrast, EGFR mutations are extremely rare in SCLC (4). However, some patients exhibit a combination subtype of SCLC and adenocarcinoma with EGFR mutation, which have been poorly investigated in terms of effective targeted therapeutic strategy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24487}
}